Transgenic Group Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Kenji Fukunaga

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	14.4yrs
Eigendom CEO	1.0%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	5.4yrs

Recente managementupdates

Recent updates

Transgenic Group Inc.'s (TSE:2342) Share Price Is Matching Sentiment Around Its Revenues

Nov 13

Improved Revenues Required Before Trans Genic Inc. (TSE:2342) Shares Find Their Feet

Apr 27

CEO

Kenji Fukunaga (55 yo)

14.4yrs

Tenure

Kenji Fukunaga has been the President of Transgenic Group Inc. (formerly known as Trans Genic Inc.) since June 2010. Kenji Fukunaga serves as the Chief Executive Officer at Trans Genic Inc and had been its...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Kenji Fukunaga	CEO, President & Representative Director	15.4yrs	geen gegevens	1.04% ¥ 34.3m
Kazuo Watanabe	GM of Accounting & Finance Department and Director	6.4yrs	geen gegevens	0.12% ¥ 4.0m
Yutaka Funabashi	GM of IR	13.4yrs	geen gegevens	0.19% ¥ 6.2m
Shunichi Kitajima	Head of CRO Business Division	no data	geen gegevens	0.18% ¥ 5.9m
Takao Sato	Outside Audit & Supervisory Board Member	16.4yrs	geen gegevens	geen gegevens
Tsutomu Seito	Independent Outside Director	13.4yrs	geen gegevens	geen gegevens
Masafumi Honbou	Outside Audit & Supervisory Board Member	4.4yrs	geen gegevens	0.090% ¥ 3.0m
Ryoji Tomonaga	Audit & Supervisory Board Member	4.4yrs	geen gegevens	geen gegevens
Hotaka Saito	Independent Outside Director	3.4yrs	geen gegevens	geen gegevens
Koji Takashima	Director	less than a year	geen gegevens	geen gegevens
Akihito Tomita	Director	less than a year	geen gegevens	0.060% ¥ 2.0m

5.4yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 2342 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.4 jaar).

Transgenic Group Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Trans Genic Inc., Annual General Meeting, Jun 20, 2024

Less than half of directors are independent

Trans Genic Inc., Annual General Meeting, Jun 23, 2022

No independent directors

Recent updates

Second quarter 2025 earnings released: JP¥4.99 loss per share (vs JP¥1.78 loss in 2Q 2024)

Transgenic Group Inc.'s (TSE:2342) Share Price Is Matching Sentiment Around Its Revenues

First quarter 2025 earnings released: JP¥5.97 loss per share (vs JP¥4.63 profit in 1Q 2024)

Full year 2024 earnings released: EPS: JP¥0.24 (vs JP¥24.28 loss in FY 2023)

Trans Genic Inc. to Report Q1, 2025 Results on Aug 09, 2024

Full year 2024 earnings released: EPS: JP¥0.24 (vs JP¥24.28 loss in FY 2023)

Trans Genic Inc., Annual General Meeting, Jun 20, 2024

Improved Revenues Required Before Trans Genic Inc. (TSE:2342) Shares Find Their Feet

Upcoming dividend of JP¥3.00 per share

Trans Genic Inc. to Report Fiscal Year 2024 Results on May 10, 2024

Third quarter 2024 earnings released: JP¥5.10 loss per share (vs JP¥7.59 profit in 3Q 2023)

New minor risk - Share price stability

Trans Genic Inc. to Report Q3, 2024 Results on Feb 09, 2024

Trans Genic Inc. (TSE:2342) announces an Equity Buyback for 300,000 shares, representing 1.78% for ¥100 million.

Second quarter 2024 earnings released: JP¥1.78 loss per share (vs JP¥4.69 profit in 2Q 2023)

Trans Genic Inc. to Report Q2, 2024 Results on Nov 10, 2023

First quarter 2024 earnings released: EPS: JP¥4.63 (vs JP¥1.49 loss in 1Q 2023)

Full year 2023 earnings released: JP¥24.28 loss per share (vs JP¥110 profit in FY 2022)

Trans Genic Inc. to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings released: JP¥24.28 loss per share (vs JP¥110 profit in FY 2022)

Upcoming dividend of JP¥5.00 per share at 0.9% yield

Third quarter 2023 earnings released: EPS: JP¥7.59 (vs JP¥10.54 loss in 3Q 2022)

Trans Genic Inc. to Report Q3, 2023 Results on Feb 10, 2023

Second quarter 2023 earnings released: EPS: JP¥4.69 (vs JP¥21.50 in 2Q 2022)

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: JP¥4.69 (vs JP¥21.50 in 2Q 2022)

Trans Genic Inc. to Report Q2, 2023 Results on Nov 11, 2022

First quarter 2023 earnings released: JP¥1.49 loss per share (vs JP¥35.01 profit in 1Q 2022)

Trans Genic Inc. to Report Q1, 2023 Results on Aug 12, 2022

Full year 2022 earnings released: EPS: JP¥110 (vs JP¥31.44 in FY 2021)

Trans Genic Inc., Annual General Meeting, Jun 23, 2022

No independent directors

Trans Genic Inc. to Report Fiscal Year 2022 Results on May 13, 2022

Upcoming dividend of JP¥3.00 per share

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Eurofins Scientific SE (ENXTPA:ERF) entered into a share purchase agreement to acquire GeneticLab Co., Ltd. from Trans Genic Inc. (TSE:2342).

Second quarter 2022 earnings released: EPS JP¥21.50 (vs JP¥2.02 in 2Q 2021)

Trans Genic Inc. (TSE:2342) entered into share transfer agreement to acquire Lunapas LLC.

Investor sentiment improved over the past week

Trans Genic Inc. (TSE:2342) announces an Equity Buyback for 550,000 shares, representing 3.17% for ¥300 million.

Full year 2021 earnings released: EPS JP¥31.44 (vs JP¥25.33 loss in FY 2020)

Full year 2021 earnings released: EPS JP¥31.44 (vs JP¥25.33 loss in FY 2020)

Third quarter 2021 earnings released: EPS JP¥24.36 (vs JP¥1.04 in 3Q 2020)

New 90-day high: JP¥549

New 90-day high: JP¥431

Trans Genic Inc. to Report Q3, 2021 Results on Feb 12, 2021

Trans Genic Inc. to Report Q2, 2021 Results on Nov 12, 2020

CEO

Tenure

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd